Reuters logo
BRIEF-Lion Biotechnologies announces updated data at 2017 ASCO from ongoing LN-144 phase 2 clinical trial
2017年6月5日 / 中午12点22分 / 3 个月前

BRIEF-Lion Biotechnologies announces updated data at 2017 ASCO from ongoing LN-144 phase 2 clinical trial

June 5 (Reuters) - Lion Biotechnologies Inc

* Lion Biotechnologies announces updated data at 2017 American Society of Clinical Oncology (ASCO) annual meeting from ongoing LN-144 phase 2 clinical trial

* Lion Biotechnologies Inc - ‍results show 77 percent of patients had reduction in target tumor size​

* Lion Biotechnologies Inc - ‍results show responses were observed in patients with tumors carrying wild type or braf mutations​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below